Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for ImmunityBio (IBRX) over the last 12 years, with Q3 2025 value amounting to $519.0 million.

  • ImmunityBio's Liabilities and Shareholders Equity rose 4235.59% to $519.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 billion, marking a year-over-year decrease of 620.01%. This contributed to the annual value of $382.9 million for FY2024, which is 2408.93% down from last year.
  • ImmunityBio's Liabilities and Shareholders Equity amounted to $519.0 million in Q3 2025, which was up 4235.59% from $402.1 million recorded in Q2 2025.
  • In the past 5 years, ImmunityBio's Liabilities and Shareholders Equity ranged from a high of $519.0 million in Q3 2025 and a low of $209.4 million during Q1 2021
  • For the 5-year period, ImmunityBio's Liabilities and Shareholders Equity averaged around $365.8 million, with its median value being $364.6 million (2024).
  • In the last 5 years, ImmunityBio's Liabilities and Shareholders Equity surged by 11181.13% in 2021 and then crashed by 2418.89% in 2025.
  • ImmunityBio's Liabilities and Shareholders Equity (Quarter) stood at $468.9 million in 2021, then fell by 22.72% to $362.4 million in 2022, then soared by 39.21% to $504.5 million in 2023, then fell by 24.09% to $382.9 million in 2024, then surged by 35.53% to $519.0 million in 2025.
  • Its last three reported values are $519.0 million in Q3 2025, $402.1 million for Q2 2025, and $303.8 million during Q1 2025.